Entrada Therapeutics (NASDAQ:TRDA) Announces Quarterly Earnings Results, Beats Expectations By $0.69 EPS

Entrada Therapeutics (NASDAQ:TRDA) announced its quarterly earnings data on Thursday. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.69, Zacks reports. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.

Entrada Therapeutics Price Performance

Shares of TRDA stock traded down $0.02 during trading on Thursday, reaching $12.00. The company had a trading volume of 79,355 shares, compared to its average volume of 112,624. The firm’s 50 day simple moving average is $14.40 and its two-hundred day simple moving average is $16.26. Entrada Therapeutics has a one year low of $11.35 and a one year high of $21.79. The company has a market capitalization of $449.19 million, a PE ratio of 7.55 and a beta of -0.17.

Insider Activity at Entrada Therapeutics

In related news, CFO Kory James Wentworth sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the transaction, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at approximately $1,476,980. This trade represents a 6.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the transaction, the insider now directly owns 4,402,849 shares in the company, valued at $91,447,173.73. The trade was a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,935 shares of company stock valued at $596,330. Corporate insiders own 7.59% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on TRDA shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Tuesday. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Oppenheimer raised their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. Finally, Roth Mkm started coverage on Entrada Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $29.00 price target for the company.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.